Sebastian Kreiter (M.D.) graduated in Medicine from the Johannes Gutenberg University in Mainz (Germany) in 1997. Clinical training in hematology and oncology (1997-2001) led him to translational science in the field of immunotherapies.
Currently he is Senior Vice President “Immunotherapy & Preclinical Research“ of BioNTech RNA Pharmaceuticals. Aside from this, he serves as board member for the Association for Cancer Immunotherapy – CIMT (http://www.cimt.eu/home). Early efforts together with Ugur Sahin from 2001 on focused on preclinical development of in-vitro transcribed mRNA cancer vaccination, which is currently under clinical testing. More recently, he took part in the pioneering development of actively personalized cancer vaccination where jointly with Ugur Sahin he worked out the scientific and technical PoC for an mRNA based mutanome vaccine in murine model systems together with his team.